Clinical Trial: A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies

U.S., April 1 -- ClinicalTrials.gov registry received information related to the study (NCT07503353) titled 'A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies' on March 25.

Brief Summary: This is a phase I/II trial of SHB-02-CD19, T-cell expressing an anti-CD19 Chimeric-Antigen-Receptor (CAR) in patients with CD19 expressing B-cell malignancies. This trial is an open label, single-arm, for pediatric and adult patients with relapsed/refractory B-cell malignancies.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: B Cell Malignancies Acute Lymphobkastic Leukemia Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell) ...